ClinicalTrials.gg
RecruitingNCT06129864eVOLVE-HNSCCUpdated Sep 30, 2026

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

A Phase 3 interventional study of volrustomig in Locally Advanced Head and Neck Squamous Cell Carcinoma, sponsored by AstraZeneca. Recruiting at 306 sites in 23 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.
Updated Sep 30, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,145
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca — 4 open to participants now, 6 under way, 2 of them phase 3. Squamous Cell Carcinoma of Head and Neck · AstraZeneca.

Planned enrollment
Largest of 21
1,145 · median 78
Started
2023
with 1 other
Phase 3
4 of 22
1 open now
Registered
19th of 22
by date

Among the 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca, this one has the largest planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2023, is one of 4 in phase 3, and was the 19th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

4 of the 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).

03

Conditions studied

  • Locally Advanced Head and Neck Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically documented locally advanced squamous cell carcinoma of the oropharynx, hypopharynx, oral cavity, or larynx with no evidence of disease (i.e. M0).
  • Confirmed unresected Stage III, Stage IVA or IVB according to the eighth edition of the American Joint Committee on Cancer (AJCC) staging manual (tumor, node, metastasis (TNM) staging system).
  • Participants will have completed definitive concurrent chemoradiotherapy (cCRT) with curative intent prior to randomization.

Exclusion criteria

Exclusion Criteria:

  • Histologically/ confirmed head and neck cancer of any other primary anatomic location in the head and neck not specified in the inclusion criteria including participants with squamous cell carcinoma of unknown primary or non-squamous histologies (eg, nasopharynx or salivary gland). Participants with >1 primary tumors are not eligible for the study.
  • Participants with any of the following:

    1. LA-HNSCC that was resected before definitive cCRT
    2. LA-HNSCC that was treated and is recurrent at the time of screening
  • Participants who have received radiotherapy (RT) alone as definitive local therapy for LA-HNSCC.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,145 participants (estimated)

Study arms

  • Experimental
    Study Arm

    Participants in this arm will receive volrustomig.

    Drug: volrustomig

  • No intervention
    Observation Arm

    Patients in this arm will undergo observation.

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) in participants with unresected LA-HNSCC with PD-L1 expressing tumors

    PFS is defined as time from randomization until first objective radiological progression per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR), or death due to any cause (in the absence of progression). The analysis will include all randomized participants with PD-L1 expressing tumors.

    Time frame: Up to approximately 8 years

Secondary outcomes

  1. Progression-Free Survival (PFS) in the unresected LA-HNSCC intent-to-treat (ITT) population

    PFS is defined as time from randomization until first objective radiological progression per RECIST 1.1 as assessed by BICR, or death due to any cause (in the absence of progression). The analysis will include all randomized participants.

    Time frame: Up to approximately 8 years

  2. Landmark Progression-Free Survival (PFS) Rates

    PFS is defined as time from randomization until first objective radiological progression per RECIST 1.1 as assessed by BICR, or death due to any cause (in the absence of progression). These analyses will include participants with PD-L1 expressing tumors and all randomized participants.

    Time frame: Up to approximately 8 years

  3. Overall Survival (OS) in participants with unresected LA-HNSCC with PD-L1 expressing tumors

    Overall survival (OS) is defined as the time from randomization until the date of death due to any cause. The analysis will include all randomized participants with PD-L1 expressing tumors.

    Time frame: Up to approximately 8 years

  4. Landmark Overall Survival (OS) Rates

    OS is defined as the time from randomization until the date of death due to any cause. These analyses will include participants with PD-L1 expressing tumors as randomized and all randomized participants.

    Time frame: Up to approximately 8 years

  5. Overall Survival (OS) in the unresected LA-HNSCC ITT population

    OS is defined as the time from randomization until the date of death due to any cause. The analysis will include all randomized participants.

    Time frame: Up to approximately 8 years

  6. Progression Free Survival 2 (PFS2)

    PFS2 is defined as the time from randomization until the earliest of the progression event (following the initial investigator-assessed progression), after the start of the first subsequent therapy, or death from any cause, whichever occurs first. The date of the second progression will be recorded by the investigator in the eCRF and defined according to local standard clinical practice. These analyses will include participants with PD-L1 expressing tumors as randomized and all randomized participants.

    Time frame: Up to approximately 8 years

  7. Presence of Anti-Drug-Antibodies (ADAs) against volrustomig in serum

    To investigate the immunogenicity of volrustomig.

    Time frame: Up to approximately 8 years

  8. Participant-reported physical functioning

    Change from baseline of physical functioning as measured by scores on the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v.20 - Physical Function 8c are reported on a T score metric (mean = 50 and SD = 10), with higher scores reflecting better physical functioning. The analysis will include all randomized participants.

    Time frame: Up to approximately 8 years

  9. Participant-reported global health status (GHS)/quality of life (QoL)

    Change from baseline of Global Health Status/Quality of Life subscale scores as measured by the European Organization for Research and Treatment of Cancer (EORTC) Item Library 172 are transformed to a 0-100 range; a higher score represents higher quality of life. The analysis will include all randomized participants.

    Time frame: Up to approximately 8 years

  10. Percentage of participants with Adverse Events

    Adverse Events as assessed by Common Terminology Criteria for Adverse Events (CTCAE).

    Time frame: Up to approximately 8 years

  11. Area under the curve (AUC)

    The concentration of Volrustomig in serum will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.

    Time frame: Up to approximately 8 years

  12. Maximum plasma concentration of the drug (Cmax)

    The concentration of Volrustomig in serum will be determined (Cmax will be derived).

    Time frame: Up to approximately 8 years

  13. The time taken to reach the maximum concentration (Tmax)

    The concentration of Volrustomig in serum will be determined (Tmax will be derived).

    Time frame: Up to approximately 8 years

07

Study locations

252 of 306 sites recruiting
  • Research Site
    Birmingham, Alabama 35233, United States
    Recruiting
  • Research Site
    Phoenix, Arizona 85028, United States
    Recruiting
  • Research Site
    Prescott Valley, Arizona 86314, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Springdale, Arkansas 72762, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Fountain Valley, California 92708, United States
    Recruiting
  • Research Site
    Fullerton, California 92835, United States
    Not yet recruiting
  • Research Site
    Los Angeles, California 90024, United States
    Recruiting
  • Research Site
    Orange, California 92868, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Santa Rosa, California 95403, United States
    Recruiting
  • Research Site
    Whittier, California 90602, United States
    Recruiting
  • Research Site
    Aurora, Colorado 80045, United States
    Recruiting
  • Research Site
    Colorado Springs, Colorado 80909, United States
    Recruiting
  • Research Site
    Lone Tree, Colorado 80124, United States
    Recruiting
  • Research Site
    Washington D.C., District of Columbia 20037, United States
    Recruiting
  • Research Site
    Fort Myers, Florida 33901, United States
    Recruiting
  • Research Site
    Gainesville, Florida 32610, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Miami, Florida 33125, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Palm Bay, Florida 32909, United States
    Recruiting
  • Research Site
    West Palm Beach, Florida 33401, United States
    Recruiting
  • Research Site
    Niles, Illinois 60714, United States
    Recruiting
  • Research Site
    Des Moines, Iowa 50309, United States
    Recruiting
  • Research Site
    Kansas City, Kansas 66160, United States
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Louisville, Kentucky 40202, United States
    Recruiting
  • Research Site
    Baton Rouge, Louisiana 70817, United States
    Recruiting
  • Research Site
    Shreveport, Louisiana 71101, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Baltimore, Maryland 21231, United States
    Recruiting
  • Research Site
    Bethesda, Maryland 20817, United States
    Recruiting
  • Research Site
    Hyattsville, Maryland 20782, United States
    Recruiting
  • Research Site
    Towson, Maryland 21204, United States
    Recruiting
  • Research Site
    Upper Marlboro, Maryland 20774, United States
    Recruiting
  • Research Site
    Boston, Massachusetts 02215, United States
    Recruiting
  • Research Site
    Fairhaven, Massachusetts 02719, United States
    Recruiting
  • Research Site
    Ann Arbor, Michigan 48105, United States
    Recruiting
  • Research Site
    Ann Arbor, Michigan 48109, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Minneapolis, Minnesota 55417, United States
    Recruiting
  • Research Site
    Columbia, Missouri 65211, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    St Louis, Missouri 63110, United States
    Recruiting
  • Research Site
    St Louis, Missouri 63110, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    East Brunswick, New Jersey 08816, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Hackensack, New Jersey 07601, United States
    Recruiting
  • Research Site
    New Brunswick, New Jersey 08901, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Albuquerque, New Mexico 87108, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    New York, New York 10065, United States
    Recruiting
  • Research Site
    New York, New York 10075, United States
    Recruiting
  • Research Site
    Stony Brook, New York 11794, United States
    Recruiting
  • Research Site
    Charlotte, North Carolina 28204, United States
    Recruiting
  • Research Site
    Winston-Salem, North Carolina 27157, United States
    Recruiting
  • Research Site
    Cleveland, Ohio 44106, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Portland, Oregon 97213, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Portland, Oregon 97239, United States
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Philadelphia, Pennsylvania 19107, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Pittsburgh, Pennsylvania 15261, United States
    Recruiting
  • Research Site
    York, Pennsylvania 17403, United States
    Recruiting
  • Research Site
    Sioux Falls, South Dakota 57104, United States
    Recruiting
  • Research Site
    Sioux Falls, South Dakota 57105, United States
    Recruiting
  • Research Site
    Nashville, Tennessee 37212, United States
    Recruiting
  • Research Site
    Austin, Texas 78745, United States
    Recruiting
  • Research Site
    Dallas, Texas 75251, United States
    Recruiting
  • Research Site
    Flower Mound, Texas 75028, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Houston, Texas 77030, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Odessa, Texas 79761, United States
    Recruiting
  • Research Site
    Tyler, Texas 75702, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Salt Lake City, Utah 84112, United States
    Recruiting
  • Research Site
    West Jordan, Utah 84088, United States
    Recruiting
  • Research Site
    Fairfax, Virginia 22031, United States
    Recruiting
  • Research Site
    Norfolk, Virginia 23502, United States
    Recruiting
  • Research Site
    Richmond, Virginia 23230, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Spokane, Washington 99204, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Tacoma, Washington 98405, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Tacoma, Washington 98415, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Graz, 8036, Austria
    Recruiting
  • Research Site
    Innsbruck, 6020, Austria
    Recruiting
  • Research Site
    Linz, 4010, Austria
    Recruiting
  • Research Site
    Salzburg, 5020, Austria
    Recruiting
  • Research Site
    Vienna, 1080, Austria
    Recruiting
  • Research Site
    Charleroi, 6060, Belgium
    Recruiting
  • Research Site
    Edegem, 2650, Belgium
    Recruiting
  • Research Site
    Jette, 1090, Belgium
    Recruiting
  • Research Site
    La Louvière, 7100, Belgium
    Recruiting
  • Research Site
    Namur, 5000, Belgium
    Recruiting
  • Research Site
    Barretos, 14784-400, Brazil
    Recruiting
  • Research Site
    Florianópolis, 88034-000, Brazil
    Recruiting
  • Research Site
    Fortaleza, 60336-045, Brazil
    Recruiting
  • Research Site
    Ijuí, 98700-000, Brazil
    Recruiting
  • Research Site
    Ipatinga, 35162-189, Brazil
    Recruiting
  • Research Site
    Londrina, 86015-520, Brazil
    Recruiting
  • Research Site
    Natal, 59075-740, Brazil
    Recruiting
  • Research Site
    Porto Alegre, 91350200, Brazil
    Recruiting
  • Research Site
    Ribeirão Preto, 14051-140, Brazil
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Rio de Janeiro, 20231-050, Brazil
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    São Paulo, 01509-900, Brazil
    Recruiting
  • Research Site
    São Paulo, 04538-132, Brazil
    Recruiting
  • Research Site
    Teresina, 64049-200, Brazil
    Recruiting
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
    Recruiting
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
    Recruiting
  • Research Site
    Kelowna, British Columbia V1Y 5L3, Canada
    Recruiting
  • Research Site
    Kingston, Ontario K7L 2V7, Canada
    Recruiting
  • Research Site
    London, Ontario N6A 5W9, Canada
    Recruiting
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
    Recruiting
  • Research Site
    Chicoutimi, Quebec G7H 5H6, Canada
    Not yet recruiting

Showing the first 100 of 306 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Apr 2030, 76 months after the start.

Of 78 phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 117. This study's planned 76 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2023
First posted
Nov 13, 2023
StartActual
Dec 14, 2023
Primary completionEst.
Apr 17, 2030
CompletionEst.
Feb 28, 2031
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 2 sites changed recruiting status (1 now withdrawn, 1 now recruiting)
Show 2 sites
  • Research Site · Bengbu, ChinaRecruiting→Withdrawn
  • Research Site · Pasig, PhilippinesNot yet recruiting→Recruiting
Show site
  • Research Site · Fullerton, United States
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    1 site added. 2 sites changed recruiting status (1 now withdrawn, 1 now recruiting)
    Show 2 sites
    • Research Site · Bengbu, ChinaRecruiting→Withdrawn
    • Research Site · Pasig, PhilippinesNot yet recruiting→Recruiting
    Show site
    • Research Site · Fullerton, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06129864
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Dec 14, 2023
Primary completion
Apr 17, 2030 (estimated)
Completion
Feb 28, 2031 (estimated)
Last update
Sep 30, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479
Robert Haddad, MD
study chair · Dana Farber Cancer Institute Massachusetts, USA
Lisa Licitra, MD
study chair · Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan Milan, Italy

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Volrustomig

Start the discussion